INSM: Rounding Bottom detected on 6 Oct 2026

INSM is forming a rounding bottom with structure score 13.0, volume score 11.0, and breakout score 13.0, yielding an overall pattern quality score of 64.0. The stock trades at $103.83 between key support at $90.39 and resistance at $161.42. Current volume of 5.39M shares is 2.17x the 20-day average, providing solid confirmation. RSI at 30.94 indicates oversold conditions—a classic setup for mean reversion. The pattern sits only 14.87% above its 52-week low but 51.2% below the 52-week high, suggesting consolidation after a significant decline.

Insmed announced on October 5, 2026 that CFO Sara Bonstein will step down on October 30 after nearly seven years, creating near-term leadership uncertainty. However, the company reaffirmed full-year 2026 guidance of $1.25–$1.40 billion for BRINSUPRI (brensocatib) and $450–$470 million for ARIKAYCE. CEO Will Lewis stated the company is "well positioned to reach cash flow positivity next year". The FDA granted priority review to ARIKAYCE for MAC lung disease with a January 28, 2027 PDUFA target. Phase 2b data for TPIP in PAH is expected in Q3 2026. Despite positive operational momentum and pipeline catalysts, the CFO transition and sector bearish regime (−0.23) weigh on sentiment.

A successful breakout above resistance at $161.42 would target a measured move of $109.59 conservatively—a 5.5% gain from current price. The 69.83% win probability suggests historical patterns of this type break upward approximately 70% of the time. Volume confirmation is critical: sustaining above $105 on continued elevated volume (>2.5M shares) would validate the setup. Invalidation occurs decisively below key support at $90.39; a break there signals failed reversal and potential continuation of the downtrend. The pattern suggests a test of intermediate resistance near $115–120 before attempting the $161.42 level.

The immediate CFO departure on October 30 creates transition risk through the October 29 earnings call. Q3 earnings are estimated October 29 with EPS loss of $0.62 and revenue of $464M—any miss could trigger accelerated selling. Sector regime is bearish (−0.23), headwind for biotech sentiment. Stock declined 18% over one month and 12% over one week; momentum remains severely negative despite oversold RSI. Elevated volatility (43.26%) and 4.92% ATR mean sharp reversals could trigger stop losses. Beta of 0.2 provides some downside protection but limits upside velocity. Regulatory approval PDUFA date (Jan 2027) is distant; no near-term catalysts besides earnings could reignite momentum.

We scan more than 6,000 NYSE and NASDAQ stocks every trading day and compare each detected pattern against a database of 370,000+ historical detections. Every setup is scored across three dimensions: Structure, Volume, and Breakout Readiness. Win probability is a calibrated estimate of how similar historical setups performed over the following 10 trading days. This is a swing trading tool built for multi-day holds. It is not built or tested for day trading.